title: Follow-up after surgery for hemorrhagic AMD.
abstract: BACKGROUND
  The long-term functional results of macular hematoma (MH) surgery in exudative AMD are often limited. The goal of this study was to compare visual outcomes of monthly versus bimestrial follow-up in these patients.
  
  
  METHODS
  Retrospective, interventional case series. Population : 21 eyes of 21 patients with SMH associated with exudative AMD.
  
  
  METHODS
  first SMH associated with exudative AMD, with 1-year postoperative follow-up.
  
  
  METHODS
  blood located exclusively underneath the retinal pigment epithelium on OCT imaging, SMH due to different etiology, lost to follow-up, ≤5 postoperative visits and a different surgical protocol as described. Patients were divided into two groups according to the number of postoperative visits (number of intravitreal injections [IVT] combined with the number of consultations, only one visit was recorded when IVT and consultation occurred on the same day) during the 1-year postoperative follow-up: group 1 had ≥11 visits (n=8); group 2 had 6 to 10 visits (n=13). All eyes underwent vitrectomy with subretinal injection of recombinant tissue plasminogen activator, fluid-gas exchange and anti-VEGF intravitreal injection. The main outcome was change in best-corrected visual acuity (BCVA).
  
  
  RESULTS
  Considering visual acuity (VA) change between 1-month and 1-year postoperative follow-up examinations, group 1 had statistically significant greater VA changes (logMAR -0.29±0.44 vs logMAR 0.42±0.73; P=0.016; P=0.016). In patients that had exudative recurrences (ER), group 1 received more anti-VEGF IVT than group 2 (P=0.045).
  
  
  CONCLUSIONS
  Our results showed that monthly follow-up, between the IVT series, is highly recommended to preserve postoperative VA in patients undergoing surgery for SMH associated with AMD.
authors.affiliation: Ophthalmology department, centre hospitalier de Bigorre, boulevard Maréchal-de-Lattre-de-Tassigny, 65000 Tarbes, France; Retina unit, ophthalmology department, hôpital Pierre-Paul-Riquet, CHU de Toulouse, place du Docteur-Baylac, TSA 40031, 31059 Toulouse cedex 9, France.
authors.forename: D
authors.initials: D
authors.lastname: Garcia
authors.affiliation: Retina unit, ophthalmology department, hôpital Pierre-Paul-Riquet, CHU de Toulouse, place du Docteur-Baylac, TSA 40031, 31059 Toulouse cedex 9, France.
authors.forename: L
authors.initials: L
authors.lastname: Mahieu
authors.affiliation: Hôtel-Dieu hospital, 75004 Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Soubrane
authors.affiliation: Retina unit, ophthalmology department, hôpital Pierre-Paul-Riquet, CHU de Toulouse, place du Docteur-Baylac, TSA 40031, 31059 Toulouse cedex 9, France.
authors.forename: L
authors.initials: L
authors.lastname: Salmon
authors.affiliation: Retina unit, ophthalmology department, hôpital Pierre-Paul-Riquet, CHU de Toulouse, place du Docteur-Baylac, TSA 40031, 31059 Toulouse cedex 9, France.
authors.forename: A
authors.initials: A
authors.lastname: Renouvin
authors.affiliation: Retina unit, ophthalmology department, hôpital Pierre-Paul-Riquet, CHU de Toulouse, place du Docteur-Baylac, TSA 40031, 31059 Toulouse cedex 9, France.
authors.forename: V
authors.initials: V
authors.lastname: Pagot-Mathis
authors.affiliation: Hôpital Nord, chemin des Bourrely, 13915 Marseille, France.
authors.forename: F
authors.initials: F
authors.lastname: Matonti
authors.affiliation: Retina unit, ophthalmology department, hôpital Pierre-Paul-Riquet, CHU de Toulouse, place du Docteur-Baylac, TSA 40031, 31059 Toulouse cedex 9, France; Laboratoire GR2DE, centre de physiopathologie de Toulouse Purpan (CPTP), place du Docteur-Baylac, TSA 40031, 31059 Toulouse cedex 9, France. Electronic address: vincesoler@yahoo.fr.
authors.forename: V
authors.initials: V
authors.lastname: Soler
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D011183:Postoperative Complications / Q000188:drug therapy; D049590:Postpartum Period; D012166:Retinal Hemorrhage / Q000150:complications / Q000601:surgery*; D012189:Retrospective Studies; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects; D014792:Visual Acuity / Q000187:drug effects; D014821:Vitrectomy; D057135:Wet Macular Degeneration / Q000150:complications / Q000601:surgery*
chemical_list: D020533:Angiogenesis Inhibitors; D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator
keywords: Activateur tissulaire du plasminogène; Anti-VEGF; DMLA exsudative; Follow-up; Injection intravitréenne; Intravitreal injection; Suivi; Tissue plasminogen activator; Vitrectomie; Vitrectomy; Wet macular degeneration